{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:21:56Z","timestamp":1793841716346,"version":"4.6.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":222,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Inhaled Antibiotic for Bronchiectasis and Cystic Fibrosis","award":["115721"],"award-info":[{"award-number":["115721"]}]},{"DOI":"10.13039\/100008593","name":"European Respiratory Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Inhaled Antibiotic for Bronchiectasis and Cystic Fibrosis","award":["115721"],"award-info":[{"award-number":["115721"]}]},{"DOI":"10.13039\/100010661","name":"European Respiratory Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Replicate phase III trials of inhaled antibiotics in patients with bronchiectasis have produced inconsistent results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study investigated if different microbial and inflammatory endotypes are linked to antibiotic response in patients with chronic Pseudomonas aeruginosa infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ORBIT-3 and ORBIT-4 were phase III trials of inhaled liposomal ciprofloxacin compared with placebo in patients with bronchiectasis with chronic P. aeruginosa infections. Baseline sputum from the trials were analyzed by 16S rRNA sequencing (LoopSeq) (n\u2009=\u2009377), proteomics (n\u2009=\u2009164), and Olink (n\u2009=\u2009117). Relationships with clinical features and frequency of exacerbations during the trials were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Patients with P. aeruginosa infections demonstrated heterogeneous endotypes. Reduced microbiota diversity was associated with exacerbation frequency (P\u2009=\u20090.021) and quality of life (P\u2009=\u20090.012). Increased exacerbations were associated with increased Pseudomonas abundance and neutrophilic inflammation; decreases in the relative abundance of commensals, including Rothia; and B-cell responses. Geographical differences were observed, with increased microbiota diversity and decreased neutrophilic inflammation in Central Europe. Candidate biomarkers for treatment response were identified, including neutrophil elastase, LSP1, and Rothia relative abundance. Before adjustment, treatment estimates of the two trials varied (ORBIT-3 rate ratio [RR], 0.85 [0.65\u20131.12], ORBIT-4 RR, 0.63 [0.48\u20130.82]). After linear discriminant analysis to adjust for microbiota profile and geographical region, the treatment estimates of ORBIT-3 (RR, 0.81 [0.54\u20131.22]) and ORBIT-4 (RR, 0.82 [0.56\u20131.22]) were similar and consistent with previous meta-analyses of inhaled antibiotics in bronchiectasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with chronic P. aeruginosa have heterogeneous microbiota and inflammatory profiles, influencing antibiotic treatment responses in bronchiectasis. Future trials could be improved by patient stratification, including accounting for geographical differences and biomarkers to represent microbiota differences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202501-0159oc","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T23:00:18Z","timestamp":1752620418000},"page":"1397-1408","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":22,"title":["Endotypes of\n                    <i>Pseudomonas aeruginosa<\/i>\n                    Infection in Bronchiectasis Are Associated with Inhaled Antibiotic Response: Results from Two Randomized, Double-Blind, Placebo-controlled Phase III Trials (ORBIT 3 and ORBIT 4)"],"prefix":"10.1093","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2014-6354","authenticated-orcid":false,"given":"Rebecca C.","family":"Hull","sequence":"first","affiliation":[{"name":"Division of Respiratory Medicine and Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4829-7440","authenticated-orcid":false,"given":"Jamie","family":"Stobo","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7572-2153","authenticated-orcid":false,"given":"Hani","family":"Abo-Leyah","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollian","family":"Richardson","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Alferes de Lima Headley","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete B.","family":"Long","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandani","family":"Hennayake","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Gilmour","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma D.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tunney","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Queen\u2019s University Belfast, Belfast, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J.","family":"Dicker","sequence":"additional","affiliation":[{"name":"Division of Population Health and Genomics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Kewin","sequence":"additional","affiliation":[{"name":"Division of Population Health and Genomics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T. J.","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Haworth","sequence":"additional","affiliation":[{"name":"Cambridge Centre for Lung Infection, Royal Papworth Hospital and University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5514-7868","authenticated-orcid":false,"given":"James D.","family":"Chalmers","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"2026031105292843300_bib1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S2213-2600(23)00093-0","article-title":"Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)","volume":"11","author":"Chalmers","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026031105292843300_bib2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","article-title":"The bronchiectasis severity index. An international derivation and validation study","volume":"189","author":"Chalmers","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031105292843300_bib3","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2213-2600(20)30557-9","article-title":"The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study","volume":"9","author":"Dicker","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026031105292843300_bib4","doi-asserted-by":"crossref","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur Respir J"},{"key":"2026031105292843300_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.chest.2024.01.045","article-title":"The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: updated systematic review and meta-analysis","volume":"166","author":"Cordeiro","year":"2024","journal-title":"Chest"},{"key":"2026031105292843300_bib6","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026031105292843300_bib7","doi-asserted-by":"crossref","first-page":"1702052","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur Respir J"},{"key":"2026031105292843300_bib8","doi-asserted-by":"crossref","first-page":"1702053","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur Respir J"},{"key":"2026031105292843300_bib9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S2213-2600(24)00225-X","article-title":"Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months","volume":"12","author":"Haworth","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026031105292843300_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026031105292843300_bib11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/pharmaceutics8010006","article-title":"Development of liposomal ciprofloxacin to treat lung infections","volume":"8","author":"Cipolla","year":"2016","journal-title":"Pharmaceutics"},{"key":"2026031105292843300_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1164\/rccm.202310-1729OC","article-title":"Endotypes of exacerbation in bronchiectasis: an observational cohort study","volume":"210","author":"Gao","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031105292843300_bib13","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1164\/rccm.202303-0499OC","article-title":"Inflammatory molecular endotypes in bronchiectasis: a European multicenter cohort study","volume":"208","author":"Choi","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031105292843300_bib14","doi-asserted-by":"crossref","first-page":"2101293","DOI":"10.1183\/13993003.01293-2021","article-title":"Rothia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease","volume":"59","author":"Rigauts","year":"2022","journal-title":"Eur Respir J"},{"issue":"Suppl 68","key":"2026031105292843300_bib15","first-page":"OA2788","article-title":"The role of microbiota in varying response to inhaled antibiotics in bronchiectasis patients with chronic Pseudomonas aeruginosa infection: a post-hoc analysis of ORBIT3 and ORBIT4 [abstract]","volume":"64","author":"Stobo","year":"2024","journal-title":"Eur Respir J"},{"issue":"Suppl 68","key":"2026031105292843300_bib16","first-page":"OA2791","article-title":"Sputum proteomics uncovers the heterogeneity of Pseudomonas aeruginosa infections in bronchiectasis [abstract]","volume":"64","author":"Hull","year":"2024","journal-title":"Eur Respir J"},{"key":"2026031105292843300_bib17","article-title":"Endotypes of Pseudomonas aeruginosa infection in bronchiectasis are associated with inhaled antibiotic response [preprint]","volume-title":"Lancet","author":"Hull"},{"key":"2026031105292843300_bib18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s40168-021-01072-3","article-title":"Ultra-accurate microbial amplicon sequencing with synthetic long reads","volume":"9","author":"Callahan","year":"2021","journal-title":"Microbiome"},{"key":"2026031105292843300_bib19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1164\/rccm.202108-1943OC","article-title":"Endotyping chronic obstructive pulmonary disease, bronchiectasis, and the \u201cchronic obstructive pulmonary disease\u2013bronchiectasis association\u201d","volume":"206","author":"Huang","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031105292843300_bib20","first-page":"1","volume-title":"Wiley StatsRef: statistics reference online","author":"Anderson","year":"2017"},{"key":"2026031105292843300_bib21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/CIRCULATIONAHA.117.033065","article-title":"Comparison of time-to-first event and recurrent-event methods in randomized clinical trials","volume":"138","author":"Claggett","year":"2018","journal-title":"Circulation"},{"key":"2026031105292843300_bib22","doi-asserted-by":"crossref","first-page":"180108","DOI":"10.1183\/16000617.0108-2018","article-title":"A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults","volume":"28","author":"Crichton","year":"2019","journal-title":"Eur Respir Rev"},{"key":"2026031105292843300_bib23","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S2213-2600(20)30504-X","article-title":"Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study","volume":"9","author":"Keir","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026031105292843300_bib24","doi-asserted-by":"crossref","first-page":"D523","DOI":"10.1093\/nar\/gkac1052","article-title":"UniProt: the Universal Protein Knowledgebase in 2023","volume":"51","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"2026031105292843300_bib25","doi-asserted-by":"crossref","first-page":"2400518","DOI":"10.1183\/13993003.00518-2024","article-title":"Bronchiectasis management in adults: state of the art and future directions","volume":"63","author":"Choi","year":"2024","journal-title":"Eur Respir J"},{"key":"2026031105292843300_bib26","doi-asserted-by":"crossref","first-page":"2000608","DOI":"10.1183\/13993003.00608-2020","article-title":"Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a post hoc analysis of the AIR-BX studies","volume":"56","author":"Crichton","year":"2020","journal-title":"Eur Respir J"},{"key":"2026031105292843300_bib27","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1183\/13993003.01888-2015","article-title":"Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration","volume":"48","author":"Aliberti","year":"2016","journal-title":"Eur Respir J"},{"key":"2026031105292843300_bib28","doi-asserted-by":"crossref","first-page":"2301966","DOI":"10.1183\/13993003.01966-2023","article-title":"Airway IL-1\u03b2 is related to disease severity and mucociliary function in bronchiectasis","volume":"64","author":"Perea","year":"2024","journal-title":"Eur Respir J"},{"key":"2026031105292843300_bib29","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-2600(24)00176-0","article-title":"Rethinking bronchiectasis as an inflammatory disease","volume":"12","author":"Long","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026031105292843300_bib30","doi-asserted-by":"crossref","first-page":"2401551","DOI":"10.1183\/13993003.01551-2024","article-title":"Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study","volume":"65","author":"Chalmers","year":"2025","journal-title":"Eur Respir J"},{"key":"2026031105292843300_bib31","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-021-01289-7","article-title":"Integrative microbiomics in bronchiectasis exacerbations","volume":"27","author":"Mac Aog\u00e1in","year":"2021","journal-title":"Nat Med"},{"key":"2026031105292843300_bib32","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.chom.2022.08.005","article-title":"Neisseria species as pathobionts in bronchiectasis","volume":"30","author":"Li","year":"2022","journal-title":"Cell Host Microbe"},{"key":"2026031105292843300_bib33","doi-asserted-by":"crossref","first-page":"230234","DOI":"10.1183\/16000617.0234-2023","article-title":"Biomarkers in bronchiectasis","volume":"33","author":"Johnson","year":"2024","journal-title":"Eur Respir Rev"},{"key":"2026031105292843300_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1164\/rccm.202306-1059OC","article-title":"Airway \u201cresistotypes\u201d and clinical outcomes in bronchiectasis","volume":"210","author":"Mac Aog\u00e1in","year":"2024","journal-title":"Am J Respir Crit Care Med"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/211\/8\/1397\/67294836\/ajrccm_211_8_1397.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/211\/8\/1397\/67294836\/ajrccm_211_8_1397.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:29:46Z","timestamp":1773221386000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/211\/8\/1397\/8513525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,1]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202501-0159oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"2025-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}